ArticleAnnals of hematology2024

Distinct pathway activities are associated with prognosis and response to bortezomib-containing treatment in MCL1-M based molecular subtypes of multiple myeloma.

Yuan Yang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.